Asset
Acalabrutinib
AstraZeneca PLC Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03198650 | phase1 | completed | 2017-06-27 | 2022-10-27 | AstraZeneca | A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies |
| NCT06564038 | phase1_2 | recruiting | 2025-01-30 | 2029-06-11 | AstraZeneca | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies |
| NCT05057494 | phase3 | active_not_recruiting | 2022-09-12 | 2027-07-15 | AstraZeneca | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT05951959 | phase2 | active_not_recruiting | 2023-12-13 | 2028-10-31 | AstraZeneca | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma |
| NCT07029737 | phase2 | recruiting | 2025-09-05 | 2027-12-31 | AstraZeneca | A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 210259 | NDA | ASTRAZENECA UK LTD |
Marketed products (1)
- CALQUENCE